Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have diagnosis of AD \>= 12 months according to the American Academy of Dermatology criteria.~* Participants must have moderate to severe AD at screening and randomization.~* Participants must have inadequate response to topical medications within 6 months of screening (or history of intolerance).~Exclusion Criteria:~* Participants must not have concurrent treatment with topical or systemic treatments for AD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 50 mg LY3375880 (Type: EXPERIMENTAL): Induction Period:~Participants received 50 mg LY3375880 administered SC Q4W.
- 150 mg LY3375880 (Type: EXPERIMENTAL): Induction Period:~Participants received 150 mg LY3375880 administered SC Q4W.
- 600 mg LY3375880 (Type: EXPERIMENTAL): Induction Period:~Participants received 600 mg LY3375880 administered SC Q4W.
- Placebo (Type: PLACEBO_COMPARATOR): Induction Period:~Participants received placebo administered subcutaneously (SC) every 4 weeks (Q4W).

Based on this trial design, predict the completion outcome and termination type (if applicable).